

## **RES-250**



# Analysis of Fluoroquinolone Resistance in ESBL-Producing *E. coli*: Genetic Determinants and Prevalence in Clinical Samples from Toyama University Hospital

Asmaa Abushwaish<sup>1</sup>, Yoshitomo Morinaga<sup>1</sup>, Hitoshi Kawasuji, Mika Morita, Makito Kaneda, Hiroshi Yamada<sup>1</sup>.

<sup>1</sup> Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama.

## Background

() Antimicrobial Resistance: ESBL-producing E. coli cause serious resistance to β-lactams and fluoroquinolones in hospitals.


#### **Genetic Focus:**

- CTX-M enzymes are the most widespread ESBLs.
- Key drivers: plasmid-mediated quinolone resistance (PMQR) genes & chromosomal mutations.

### **Study Goal:**

- Characterize CTX-M groups, PMQR, and chromosomal mutations.
- Assess links to patient characteristics using PCR & WGS.

#### Methods



- Sept 2023 Apr 2024
- Sources: urine, blood, others
- CTX-M, PMQR and **Chromosomal Mutation**
- Prior antibiotic use
- Hospitalization Hx.
- Mutation co-occurrence
- Patient associations

#### Results



Figure 1. Distribution of CTX-M Groups Among Clinical Isolates




Figure 2. Distribution of Gene Mutation Combinations Among CTX-M Groups





Figure 3. Distribution of Chromosomal Mutations and PMQR Genes Among ESBL E. coli Isolates








Figure 5. Association Between gyrA and parE Mutations




Figure 6. Association Between gyrA and parC Mutations

Characteristic	CTX-M-1 (n=19)	CTX-M-9 (n=22)	Total (n=41)	p-value
Sex (Male)	8 (42.1%)	13 (56.5%)	21	0.54
Antibiotic use (1 mo)	11 (57.9%)	10 (43.5%)	21	0.54
Antibiotic use (3 mo)	7 (36.9%)	4 (17.4%)	11	0.18
Hospitalization (1 mo)	4 (21.1%)	4 (17.4%)	8	1.00

**Table 1.** Clinical and Demographic Profiles of Patients With CTX-M-1 and CTX-M-9 Isolates

#### Conclusion

- •WGS outperformed PCR for CTX-M detection, especially in the CTX-M-1 group (p < 0.0001).
- •High prevalence of QRDR mutations: gyrA (87.5%), parC (75.6%), parE (78.0%).
- •Significant co-occurrence of parE-parC, gyrA-parC and gyrA-parE mutations (p < 0.0001).
- •PMQR genes were rare but detected alongside CTX-M variants.
- •No demographic associations, indicating silent transmission.